Literature DB >> 18981295

Phosphoantigen-activated V gamma 2V delta 2 T cells antagonize IL-2-induced CD4+CD25+Foxp3+ T regulatory cells in mycobacterial infection.

Guangming Gong1, Lingyun Shao, Yunqi Wang, Crystal Y Chen, Dan Huang, Shuyu Yao, Ximei Zhan, Helene Sicard, Richard Wang, Zheng W Chen.   

Abstract

Although Foxp3(+) T regulatory cells (Tregs) are well documented for their ability to suppress various immune cells, T-cell subsets capable of counteracting Tregs have not been demonstrated. Here, we assessed phosphoantigen-activated Vgamma2Vdelta2 T cells for the ability to interplay with Tregs in the context of mycobacterial infection. A short-term IL-2 treatment regimen induced marked expansion of CD4(+)CD25(+)Foxp3(+) T cells and subsequent suppression of mycobacterium-driven increases in numbers of Vgamma2Vdelta2 T cells. Surprisingly, activation of Vgamma2Vdelta2 T cells by adding phosphoantigen Picostim to the IL-2 treatment regimen down-regulated IL-2-induced expansion of CD4(+)CD25(+)Foxp3(+) T cells. Consistently, in vitro activation of Vgamma2Vdelta2 T cells by phosphoantigen plus IL-2 down-regulated IL-2-induced expansion of CD4(+)CD25(+)Foxp3(+) T cells. Interestingly, anti-IFN-gamma-neutralizing antibody, not anti-TGF-beta or anti-IL-4, reduced the ability of activated Vgamma2Vdelta2 T cells to down-regulate Tregs, suggesting that autocrine IFN-gamma and its network contributed to Vgamma2Vdelta2 T cells' antagonizing effects. Furthermore, activation of Vgamma2Vdelta2 T cells by Picostim plus IL-2 treatment appeared to reverse Treg-driven suppression of immune responses of phosphoantigen-specific IFNgamma(+) or perforin(+) Vgamma2Vdelta2 T cells and PPD-specific IFNgamma(+)alphabeta T cells. Thus, phos-phoantigen activation of Vgamma2Vdelta2 T cells antagonizes IL-2-induced expansion of Tregs and subsequent suppression of Ag-specific antimicrobial T-cell responses in mycobacterial infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18981295      PMCID: PMC2630269          DOI: 10.1182/blood-2008-06-162792

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  44 in total

1.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.

Authors:  Estelle Bettelli; Yijun Carrier; Wenda Gao; Thomas Korn; Terry B Strom; Mohamed Oukka; Howard L Weiner; Vijay K Kuchroo
Journal:  Nature       Date:  2006-04-30       Impact factor: 49.962

Review 2.  Control of NK cell functions by CD4+CD25+ regulatory T cells.

Authors:  Natacha Ralainirina; Aurélie Poli; Tatiana Michel; Linda Poos; Emmanuel Andrès; François Hentges; Jacques Zimmer
Journal:  J Leukoc Biol       Date:  2006-09-07       Impact factor: 4.962

3.  Lipopolysaccharide-activated CD4+CD25+ T regulatory cells inhibit neutrophil function and promote their apoptosis and death.

Authors:  Przemyslaw Lewkowicz; Natalia Lewkowicz; Andrzej Sasiak; Henryk Tchórzewski
Journal:  J Immunol       Date:  2006-11-15       Impact factor: 5.422

4.  Human CD4+CD25high regulatory T cells modulate myeloid but not plasmacytoid dendritic cells activation.

Authors:  Roch Houot; Ivan Perrot; Eric Garcia; Isabelle Durand; Serge Lebecque
Journal:  J Immunol       Date:  2006-05-01       Impact factor: 5.422

5.  Origin and T cell receptor diversity of Foxp3+CD4+CD25+ T cells.

Authors:  Rafal Pacholczyk; Hanna Ignatowicz; Piotr Kraj; Leszek Ignatowicz
Journal:  Immunity       Date:  2006-08-03       Impact factor: 31.745

6.  IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients.

Authors:  Mojgan Ahmadzadeh; Steven A Rosenberg
Journal:  Blood       Date:  2005-11-22       Impact factor: 22.113

7.  IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo.

Authors:  Emmanuel Zorn; Erik A Nelson; Mehrdad Mohseni; Fabrice Porcheray; Haesook Kim; Despina Litsa; Roberto Bellucci; Elke Raderschall; Christine Canning; Robert J Soiffer; David A Frank; Jerome Ritz
Journal:  Blood       Date:  2006-04-27       Impact factor: 22.113

8.  In vivo immunomanipulation of V gamma 9V delta 2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model.

Authors:  Hélène Sicard; Sophie Ingoure; Béatrice Luciani; Claire Serraz; Jean-Jacques Fournié; Marc Bonneville; Jérôme Tiollier; François Romagné
Journal:  J Immunol       Date:  2005-10-15       Impact factor: 5.422

9.  Most human thymic and peripheral-blood CD4+ CD25+ regulatory T cells express 2 T-cell receptors.

Authors:  Heli Tuovinen; Jukka T Salminen; T Petteri Arstila
Journal:  Blood       Date:  2006-08-22       Impact factor: 22.113

10.  Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells.

Authors:  Hua Zhang; Kevin S Chua; Martin Guimond; Veena Kapoor; Margaret V Brown; Thomas A Fleisher; Lauren M Long; Donna Bernstein; Brenna J Hill; Daniel C Douek; Jay A Berzofsky; Charles S Carter; E J Read; Lee J Helman; Crystal L Mackall
Journal:  Nat Med       Date:  2005-10-16       Impact factor: 53.440

View more
  36 in total

1.  Membrane-bound IL-22 after de novo production in tuberculosis and anti-Mycobacterium tuberculosis effector function of IL-22+ CD4+ T cells.

Authors:  Gucheng Zeng; Crystal Y Chen; Dan Huang; Shuyu Yao; Richard C Wang; Zheng W Chen
Journal:  J Immunol       Date:  2011-06-01       Impact factor: 5.422

2.  HMBPP Analog Prodrugs Bypass Energy-Dependent Uptake To Promote Efficient BTN3A1-Mediated Malignant Cell Lysis by Vγ9Vδ2 T Lymphocyte Effectors.

Authors:  Ashley M Kilcollins; Jin Li; Chia-Hung Christine Hsiao; Andrew J Wiemer
Journal:  J Immunol       Date:  2016-06-06       Impact factor: 5.422

Review 3.  Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside.

Authors:  Barbara Castella; Candida Vitale; Marta Coscia; Massimo Massaia
Journal:  Cell Mol Life Sci       Date:  2011-05-17       Impact factor: 9.261

Review 4.  Modulators of microglial activation and polarization after intracerebral haemorrhage.

Authors:  Xi Lan; Xiaoning Han; Qian Li; Qing-Wu Yang; Jian Wang
Journal:  Nat Rev Neurol       Date:  2017-05-19       Impact factor: 42.937

Review 5.  CD8 T cells and Mycobacterium tuberculosis infection.

Authors:  Philana Ling Lin; JoAnne L Flynn
Journal:  Semin Immunopathol       Date:  2015-04-28       Impact factor: 9.623

Review 6.  Gamma-delta T-cell lymphomas.

Authors:  Claudio Tripodo; Emilio Iannitto; Ada Maria Florena; Carlo Ennio Pucillo; Pier Paolo Piccaluga; Vito Franco; Stefano Aldo Pileri
Journal:  Nat Rev Clin Oncol       Date:  2009-11-10       Impact factor: 66.675

Review 7.  What lessons can be learned from γδ T cell-based cancer immunotherapy trials?

Authors:  Jean-Jacques Fournié; Hélène Sicard; Mary Poupot; Christine Bezombes; Amandine Blanc; François Romagné; Loic Ysebaert; Guy Laurent
Journal:  Cell Mol Immunol       Date:  2012-12-17       Impact factor: 11.530

8.  DR*W201/P65 tetramer visualization of epitope-specific CD4 T-cell during M. tuberculosis infection and its resting memory pool after BCG vaccination.

Authors:  Huiyong Wei; Richard Wang; Zhuqing Yuan; Crystal Y Chen; Dan Huang; Lisa Halliday; Weihua Zhong; Gucheng Zeng; Yun Shen; Ling Shen; Yunqi Wang; Zheng W Chen
Journal:  PLoS One       Date:  2009-09-04       Impact factor: 3.240

9.  Differentiation, distribution and gammadelta T cell-driven regulation of IL-22-producing T cells in tuberculosis.

Authors:  Shuyu Yao; Dan Huang; Crystal Y Chen; Lisa Halliday; Gucheng Zeng; Richard C Wang; Zheng W Chen
Journal:  PLoS Pathog       Date:  2010-02-26       Impact factor: 6.823

10.  NSOM/QD-based direct visualization of CD3-induced and CD28-enhanced nanospatial coclustering of TCR and coreceptor in nanodomains in T cell activation.

Authors:  Liyun Zhong; Gucheng Zeng; Xiaoxu Lu; Richard C Wang; Guangming Gong; Lin Yan; Dan Huang; Zheng W Chen
Journal:  PLoS One       Date:  2009-06-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.